PERLage is multicentre observational study following the participants from the PERL study. PERLage allows study of the long-term effects of 3 years of serum uric acid reduction and, more broadly, of the natural history and the determinants of kidney function loss in type 1 diabetes subjects.
- To investigate the long-term effects of allopurinol treatment on kidney function in persons with T1D and mild to moderate diabetic kidney disease (DKD),
- To study the long-term effects of allopurinol treatment on cardiovascular (CV) and eye complications,
- To identify additional clinical and demographic characteristics of persons with T1D that are predictive of regression, stability, or progression of mild to moderate DKD, and
- To identify novel serum, urinary, and tissue biomarkers of rates of kidney function loss, progression to ESRD, and eye and cardiovascular co-morbidities or of protection from these events in these subjects.
Joslin Diabetes Center (Boston, USA) and the rest of the PERLage sites in USA and Canada (16 sites in total).